Coeptis TherapeuticsCOEP
About: Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
Employees: 7
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
0.24% less ownership
Funds ownership: 1.64% [Q1] → 1.4% (-0.24%) [Q2]
11% less funds holding
Funds holding: 9 [Q1] → 8 (-1) [Q2]
26% less capital invested
Capital invested by funds: $518K [Q1] → $384K (-$134K) [Q2]
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Research analyst outlook
We haven’t received any recent analyst ratings for COEP.
Financial journalist opinion









